The U.S. Patent and Trademark Office has granted U.S. patent 8,575,172 to Zysis, covering its Phase II-ready Long Acting Oral Aripiprazole Once Weekly (LAO Aripiprazole OW) product, a first-in-class antipsychotic therapy for orally dosed relapse prevention in patients suffering from schizophrenia and bipolar disorders. The patent covers the treatment of psychotic conditions with orally-delivered formulations of aripiprazole that provide for sustained-release, once-weekly therapy. Patents have a...